Chemokine biology on immune checkpoint –targeted therapies

The use of antagonistic immune checkpoint –targeted monoclonal antibodies has profoundly modified the standard of care and significantly increased the survival for many cancers. However, many patients still do not respond to those treatments. Biomarkers predictive for efficacy or failure of such immunotherapies would allow developing trea tment stratification strategies which could further increase the survival rates of patients with cancer. Chemokines are a subset of the immune cell messenger molecules known as cytokines.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Review Source Type: research